1. Jorgensen J, Pfaller M, editors. Manual of Clinical Microbiology. 11th ed. Washington: ASM Press;2015. p. 295.
2. Kashyap S, Pandey A, Thakuria B, Saxena AK, Asthana AK, Madan M. Resistant microorganisms isolated from cases of chronic suppurative otitis media: a therapeutic concern. Nat J Lab Med. 2017; 6:MC01–MC06.
3. Dagan R. Clinical significance of resistant organisms in otitis media. Pediatr Infect Dis J. 2000; 19:378–382.
4. Rosenfeld RM, Schwartz SR, Cannon CR, Roland PS, Simon GR, Kumar KA, et al. Clinical practice guideline: acute otitis externa. Otolaryngol Head Neck Surg. 2014; 150:1 Suppl. S1–24.
5. van Cauwenberge PB, Vander Mijnsbrugge AM, Ingels KJ. The microbiology of acute and chronic sinusitis and otitis media:a review. Eur Arch Otorhinolaryngol. 1993; 250 Suppl 1:S3–S6.
6. Kumar H, Seth S. Bacterial and fungal study of 100 cases of chronic suppurative otitis media. J Clin Diagn Res. 2011; 5:1224–1227.
7. Ali K, Hamed MA, Hassan H, Esmail A, Sheneef A. Identification of fungal pathogens in otomycosis and their drug sensitivity: our experience. Int Arch Otorhinolaryngol. 2018; 22:400–403.
8. Heo MS, Shin JH, Choi MJ, Park YJ, Lee HS, Koo SH, et al. Molecular identification and amphotericin B susceptibility testing of clinical isolates of Aspergillus from 11 hospitals in Korea. Ann Lab Med. 2015; 35:602–610.
9. Kim MN, Shin JH, Sung H, Lee K, Kim EC, Ryoo N, et al. Candida haemulonii and closely related species at 5 university hospitals in Korea: identification, antifungal susceptibility, and clinical features. Clin Infect Dis. 2009; 48:e57–e61.
10. Satoh K, Makimura K, Hasumi Y, Nishiyama Y, Uchida K, Yamaguchi H. Candida auris sp. nov., a novel ascomycetous yeast isolated from the external ear canal of an inpatient in a Japanese hospital. Microbiol Immunol. 2009; 53:41–44.
11. Lee WG, Shin JH, Uh Y, Kang MG, Kim SH, Park KH, et al. First three reported cases of nosocomial fungemia caused by Candida auris. J Clin Microbiol. 2011; 49:3139–3142.
12. Mizusawa M, Miller H, Green R, Lee R, Durante M, Perkins R, et al. Can multidrug-resistant Candida auris be reliably identified in clinical microbiology laboratories? J Clin Microbiol. 2017; 55:638–640.
13. Prakash A, Sharma C, Singh A, Kumar Singh P, Kumar A, Hagen F, et al. Evidence of genotypic diversity among Candida auris isolates by multilocus sequence typing, matrix-assisted laser desorption ionization time-of-flight mass spectrometry and amplified fragment length polymorphism. Clin Microbiol Infect. 2016; 22:277.e1–277.e9.
14. CLSI. Reference method for broth dilution antifungal susceptibility testing of yeasts: approved standard. CLSI document M27-A3. Wayne, PA: Clinical and Laboratory Standards Institute;2008.
15. CLSI. Performance standards for antifungal susceptibility testing of yeasts. CLSI document M60. Wayne, PA: Clinical and Laboratory Standards Institute;2017.
16. Pfaller MA, Diekema DJ. Progress in antifungal susceptibility testing of Candida spp. by use of Clinical and Laboratory Standards Institute broth microdilution methods, 2010 to 2012. J Clin Microbiol. 2012; 50:2846–2856.
18. Viswanatha B, Naseeruddin K. Fungal infections of the ear in immunocompromised host: a review. Mediterr J Hematol Infect Dis. 2011; 3:e2011003.
19. Tavanti A, Davidson AD, Gow NA, Maiden MC, Odds FC. Candida orthopsilosis and Candida metapsilosis spp. nov. to replace Candida parapsilosis groups II and III. J Clin Microbiol. 2005; 43:284–292.
20. Vennewald I, Schönlebe J, Klemm E. Mycological and histological investigations in humans with middle ear infections. Mycoses. 2003; 46:12–18.
21. Silva AP, Miranda IM, Lisboa C, Pina-Vaz C, Rodrigues AG. Prevalence, distribution, and antifungal susceptibility profiles of Candida parapsilosis, C. orthopsilosis, and C. metapsilosis in a tertiary care hospital. J Clin Microbiol. 2009; 47:2392–2397.
22. Lee HS, Shin JH, Choi MJ, Won EJ, Kee SJ, Kim SH, et al. Comparison of the Bruker Biotyper and VITEK MS matrixassisted laser desorption/ionization time-of-flight mass spectrometry systems using a formic acid extraction method to identify common and uncommon yeast isolates. Ann Lab Med. 2017; 37:223–230.
23. Jung J, Kim MJ, Kim JY, Lee JY, Kwak SH, Hong MJ, et al.
Candida auris colonization or infection of the ear: a single-center study in South Korea from 2016 to 2018. Med Mycol. 2019; myz020. DOI:
10.1093/mmy/myz020. [Epub ahead of print].
24. Kwon YJ, Shin JH, Byun SA, Choi MJ, Won EJ, Lee D, et al. Candida auris clinical isolates from South Korea: identification, antifungal susceptibility, and genotyping. J Clin Microbiol. 2019; 57:e01624-18.
25. Tay ST, Na SL, Chong J. Molecular differentiation and antifungal susceptibilities of Candida parapsilosis isolated from patients with bloodstream infections. J Med Microbiol. 2009; 58(Pt 2):185–191.
26. Welsh RM, Bentz ML, Shams A, Houston H, Lyons A, Rose LJ, et al. Survival, persistence, and isolation of the emerging multidrug-resistant pathogenic yeast Candida auris on a plastic health care surface. J Clin Microbiol. 2017; 55:2996–3005.
27. Trofa D, Gácser A, Nosanchuk JD. Candida parapsilosis, an emerging fungal pathogen. Clin Microbiol Rev. 2008; 21:606–625.
28. van Asbeck EC, Clemons KV, Stevens DA. Candida parapsilosis: a review of its epidemiology, pathogenesis, clinical aspects, typing and antimicrobial susceptibility. Crit Rev Microbiol. 2009; 35:283–309.
29. Choi YJ, Kim YJ, Yong D, Byun JH, Kim TS, Chang YS, et al. Fluconazole-resistant Candida parapsilosis bloodstream isolates with Y132F mutation in ERG11 gene, South Korea. Emerg Infect Dis. 2018; 24:1768–1770.
30. Lockhart SR, Etienne KA, Vallabhaneni S, Farooqi J, Chowdhary A, Govender NP, et al. Simultaneous emergence of multidrugresistant Candida auris on 3 continents confirmed by whole-genome sequencing and epidemiological analyses. Clin Infect Dis. 2017; 64:134–140.
31. Chowdhary A, Anil Kumar V, Sharma C, Prakash A, Agarwal K, Babu R, et al. Multidrug-resistant endemic clonal strain of Candida auris in India. Eur J Clin Microbiol Infect Dis. 2014; 33:919–926.
32. Kathuria S, Singh PK, Sharma C, Prakash A, Masih A, Kumar A, et al. Multidrug-resistant Candida auris misidentified as Candida haemulonii: characterization by matrix-assisted laser desorption ionization-time of flight mass spectrometry and DNA sequencing and its antifungal susceptibility profile variability by Vitek 2, CLSI broth microdilution, and Etest method. J Clin Microbiol. 2015; 53:1823–1830.
33. Chowdhary A, Sharma C, Meis JF. Candida auris: a rapidly emerging cause of hospital-acquired multidrug-resistant fungal infections globally. PLoS Pathog. 2017; 13:e1006290.
34. Dobb KS, Kaye SJ, Beckmann N, Thain JL, Stateva L, Birch M, et al. Characterisation of the Candida albicans phosphopantetheinyl transferase Ppt2 as a potential antifungal drug target. PLoS One. 2015; 10:e0143770.
35. Won EJ, Shin JH, Choi MJ, Lee WG, Park YJ, Uh Y, et al. Antifungal susceptibilities of bloodstream isolates of Candida species from nine hospitals in Korea: application of new antifungal breakpoints and relationship to antifungal usage. PLoS One. 2015; 10:e0118770.
36. Verhoeff M, van der Veen EL, Rovers MM, Sanders EA, Schilder AG. Chronic suppurative otitis media: a review. Int J Pediatr Otorhinolaryngol. 2006; 70:1–12.
37. Ibekwe AO, al Shareef Z, Benayam A. Anaerobes and fungi in chronic suppurative otitis media. Ann Otol Rhinol Laryngol. 1997; 106:649–652.
38. Pekard-Amenitsch S, Schriebl A, Posawetz W, Willinger B, Kölli B, Buzina W. Isolation of Candida auris from ear of otherwise healthy patient, Austria, 2018. Emerg Infect Dis. 2018; 24:1596–1597.
39. Schwartz IS, Hammond GW. First reported case of multidrugresistant Candida auris in Canada. Can Commun Dis Rep. 2017; 43:150–153.
40. Yang A, Carlton DA, Hamula C, Patel G, Iloreta AMC. First prospectively identified case of Candida auris in the United States. Otolaryngol Case Rep. 2017; 5:6–7.